ProQR Therapeutics (NASDAQ:PRQR) Share Price Crosses Above 50 Day Moving Average - What's Next?

ProQR Therapeutics N.V. (NASDAQ:PRQR - Get Free Report)'s share price crossed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $1.81 and traded as high as $2.17. ProQR Therapeutics shares last traded at $2.14, with a volume of 190,621 shares changing hands.

Analysts Set New Price Targets

PRQR has been the topic of several research analyst reports. Chardan Capital reiterated a "buy" rating and issued a $4.00 price target on shares of ProQR Therapeutics in a research note on Friday, March 14th. Evercore ISI began coverage on ProQR Therapeutics in a research note on Tuesday, April 29th. They set an "outperform" rating and a $5.00 price target for the company. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $8.00 price objective on shares of ProQR Therapeutics in a research note on Friday, June 27th. HC Wainwright increased their target price on ProQR Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a research report on Friday, March 14th. Finally, JMP Securities reissued a "market outperform" rating and issued a $8.00 target price on shares of ProQR Therapeutics in a report on Friday, June 27th. One research analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, ProQR Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $8.00.

ProQR Therapeutics Stock Up 4.5%

The stock's fifty day moving average price is $1.83 and its 200 day moving average price is $1.93.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02). ProQR Therapeutics had a negative return on equity of 53.49% and a negative net margin of 157.04%. The company had revenue of $4.89 million for the quarter, compared to analysts' expectations of $4.90 million. On average, research analysts predict that ProQR Therapeutics N.V. will post -0.31 EPS for the current year.

Hedge Funds Weigh In On ProQR Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in PRQR. Jane Street Group LLC bought a new stake in shares of ProQR Therapeutics in the 4th quarter valued at about $30,000. Invesco Ltd. acquired a new stake in ProQR Therapeutics in the fourth quarter valued at approximately $32,000. Alpine Global Management LLC purchased a new position in ProQR Therapeutics in the fourth quarter worth $39,000. Two Sigma Securities LLC purchased a new stake in shares of ProQR Therapeutics during the 4th quarter valued at $40,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of ProQR Therapeutics in the 4th quarter worth $54,000. Hedge funds and other institutional investors own 32.65% of the company's stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).